Literature DB >> 27807709

Prognostic Significance of the Proportion of Tall Cell Components in Papillary Thyroid Carcinoma.

Yasuhiro Ito1, Mitsuyoshi Hirokawa2, Akira Miyauchi3, Takuya Higashiyama3, Minoru Kihara3, Akihiro Miya3.   

Abstract

AIM: Tall cell variant (TCV) of papillary thyroid carcinoma (PTC) shows a poorer prognosis than conventional PTC. The World Health Organization (WHO) classification defines TCV as the tall cell component (TCC) in ≥50% of PTC lesions. We investigated whether and how the proportion of TCC affects the prognosis of patients with PTC with TCC. PATIENTS AND METHODS: Seventy patients with TCC in ≥30% of their PTC lesions and 210 age- and gender-matched controls with no TCC who underwent locally curative surgery at Kuma Hospital (2006-2014) were enrolled. The 70 PTC patients were divided into two categories: TCC ≥50% (TCC-major, n = 19) and TCC 30-49% (TCC-minor, n = 51). We performed univariate and multivariate analyses of the relationships between disease-free survival (DFS) and variables including the TCC proportion in 276 patients who had no distant metastases at surgery (median follow-up 64 months).
RESULTS: In the univariate analysis, TCC-major, TCC-minor, old age (≥65 years), clinical node metastasis, significant extrathyroid extension (Ex), and high Ki-67 labeling index (≥5%) significantly affected the DFS. In the multivariate analysis, TCC-major and Ex independently affected the DFS, but TCC-minor did not. In an analysis excluding TCC-major patients, TCC-minor was not an independent prognostic factor for DFS.
CONCLUSIONS: Studies or larger patient series with longer follow-ups are necessary, but we speculate that in PTC with TCC, TCC-major significantly and independently affects the DFS, whereas TCC-minor does not. Our findings indicate that the WHO definition of TCV is appropriate and that the prognostic impact of TCC-minor is limited.

Entities:  

Mesh:

Year:  2017        PMID: 27807709     DOI: 10.1007/s00268-016-3784-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

2.  Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer.

Authors:  Takashi Uruno; Akira Miyauchi; Kazuo Shimizu; Chisato Tomoda; Yuuki Takamura; Yasuhiro Ito; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Nobuyuki Amino; Kanji Kuma
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

3.  Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation.

Authors:  Yasuhiro Ito; Akira Miyauchi; Minoru Kihara; Takuya Higashiyama; Kaoru Kobayashi; Akihiro Miya
Journal:  Thyroid       Date:  2013-11-14       Impact factor: 6.568

4.  Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Akira Miyauchi; Kennichi Kakudo; Mitsuyoshi Hirokawa; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

5.  Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival.

Authors:  Luc G T Morris; Ashok R Shaha; R Michael Tuttle; Andrew G Sikora; Ian Ganly
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

6.  Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysis.

Authors:  Scharukh Jalisi; Tiffiny Ainsworth; Michael Lavalley
Journal:  J Thyroid Res       Date:  2010-07-26

7.  Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma.

Authors:  Toni Beninato; Theresa Scognamiglio; David A Kleiman; Alessia Uccelli; Daniela Vaca; Thomas J Fahey; Rasa Zarnegar
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

8.  Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan.

Authors:  Yasuhiro Ito; Mitsuyoshi Hirokawa; Mitsuhiro Fukushima; Hiroyuki Inoue; Tomonori Yabuta; Takashi Uruno; Minoru Kihara; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Akira Miyauchi
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

9.  Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Authors:  Xiaoguang Shi; Rengyun Liu; Fulvio Basolo; Riccardo Giannini; Xiaopei Shen; Di Teng; Haixia Guan; Zhongyan Shan; Weiping Teng; Thomas J Musholt; Khawla Al-Kuraya; Laura Fugazzola; Carla Colombo; Electron Kebebew; Barbara Jarzab; Agnieszka Czarniecka; Bela Bendlova; Vlasta Sykorova; Manuel Sobrinho-Simões; Paula Soares; Young Kee Shong; Tae Yong Kim; Sonia Cheng; Sylvia L Asa; David Viola; Rossella Elisei; Linwah Yip; Caterina Mian; Federica Vianello; Yangang Wang; Shihua Zhao; Gisele Oler; Janete M Cerutti; Efisio Puxeddu; Shen Qu; Qing Wei; Huixiong Xu; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hongyu Yu; Giovanni Tallini; Elizabeth H Holt; Vasily Vasko; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2015-11-03       Impact factor: 5.958

10.  Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications.

Authors:  Ronald A Ghossein; Rebecca Leboeuf; Kepal N Patel; Michael Rivera; Nora Katabi; Diane L Carlson; Giovanni Tallini; Ashok Shaha; Buvanesh Singh; R Michael Tuttle
Journal:  Thyroid       Date:  2007-07       Impact factor: 6.568

View more
  6 in total

1.  Letter to the Editor: Reply.

Authors:  Yasuhiro Ito; Akira Miyauchi; Mitsuyoshi Hirokawa
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

2.  Prognostic Significance of the Proportion of Tall Cell Components in Papillary Thyroid Carcinoma.

Authors:  Sapana Bothra; Aromal Chekavar; Sabaretnam Mayilvaganan
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

3.  Diagnostic clues indicating tall cell variants of papillary thyroid carcinoma in fine needle aspiration.

Authors:  Aki Tanaka; Mitsuyoshi Hirokawa; Miyoko Higuchi; Ayana Suzuki; Naoki Yamao; Toshitetsu Hayashi; Seiji Kuma; Akira Miyauchi
Journal:  Diagn Cytopathol       Date:  2018-12-23       Impact factor: 1.582

4.  Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors.

Authors:  Oleksiy Tsybrovskyy; Monica De Luise; Dario de Biase; Leonardo Caporali; Claudio Fiorini; Giuseppe Gasparre; Valerio Carelli; Dominik Hackl; Larisa Imamovic; Silke Haim; Manuel Sobrinho-Simões; Giovanni Tallini
Journal:  J Pathol Clin Res       Date:  2021-11-17

Review 5.  Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis.

Authors:  Huy Gia Vuong; Nguyen Phuoc Long; Nguyen Hoang Anh; Tran Diem Nghi; Mai Van Hieu; Le Phi Hung; Tadao Nakazawa; Ryohei Katoh; Tetsuo Kondo
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

6.  Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study.

Authors:  Mijin Kim; Sun Wook Cho; Young Joo Park; Hwa Young Ahn; Hee Sung Kim; Yong Joon Suh; Dughyun Choi; Bu Kyung Kim; Go Eun Yang; Il-Seok Park; Ka Hee Yi; Chan Kwon Jung; Bo Hyun Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.